DiscoverRessources
All our news
ITCC-P4, first company in the world to offer preclinical drug tests for children with cancer
Discover
Publications
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Discover
Publications
Targeting genome integrity dysfunctions impedes metastatic potency in non-small-cell lung cancer circulating tumor cellderived eXplants
CTC-derived eXplants (CDX) offer systems for mechanistic investigation of CTC metastatic potency and may provide rationale for biology-driven therapeutics.
Discover
Publications
STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway – Oncogene, Oct.8 2021
Discover
news
ITCC-P4, first company in the world to offer preclinical drug tests for children with cancer
Discover
news
XenTech remains fully operational after 7 weeks of COVID-19 pandemic : update from our COO
In this 7th week of containment and as end of confinement in France is announced for May 11th, I would first of all like to thank you on behalf of our teams for all the messages of support you have sent us since the beginning of the COVID-19 crisis.
Discover
news
XenTech Covid-19 management
Regarding the current circumstances, we at XenTech want you to know that we are taking the Covid-19 pandemia very seriously. We are closely monitoring the pandemic, following guidance and advice from the World Health Organization (WHO), and the French Government.
Discover
publications
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Discover
publications
Targeting genome integrity dysfunctions impedes metastatic potency in non-small-cell lung cancer circulating tumor cellderived eXplants
CTC-derived eXplants (CDX) offer systems for mechanistic investigation of CTC metastatic potency and may provide rationale for biology-driven therapeutics.
Discover
publications
STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway – Oncogene, Oct.8 2021
Discover
publications
Paediatric Liver Cancer
A preclinical platform of mouse-transplanted human pediatric liver tumors to evaluate the efficacy of conventional and innovative anticancer therapy
Discover
01Conferences & events
04.14.23
XenTech will attend AACR Annual Meeting in Orlando (Apr. 14-19 2023)
Philippe, Olivier and Delphine cordially invite you to stop by our Booth#618 to discuss our solid tumor PDX collection to bring your innovative research projects a step further !
Discover
03.13.23
XenTech will attend the World ADC London (Mar.- 13-16th)
Philippe and Olivier cordially invite you to stop by our Booth#12 to discuss our long experience in testing ADCs in our solid tumor PDX collection !
Discover
01.24.23
XenTech will attend the DDR inhibitors Summit 2023 (Boston, Jan. 24-26)
Our Head of R&D Oliver Déas will be delighted to discuss with you as he'll be attending in person.
Discover
06.20.22
XenTech exhibits at EACR 2022 (Seville, Jun. 20-23 2022)
We'll be exhibiting at EACR in Seville, stop by booth #50 !
Discover
